Uses Warnings Before taking Dosage Side effects Interactions FAQ What is Kadcyla?Kadcyla is a cancer medicine that interferes with the growth and spread of cancer cells in the body.Kadcyla is used to treat HER2-positive breast cancer.Kadcyla is used both for early breast cancer and for breast ...
Cardiac Toxicity: KADCYLA administration may lead to reductions in left ventricular ejection fraction (LVEF). Evaluate left ventricular function in all patients prior to and during treatment with KADCYLA. Withhold treatment for clinically significant decrease in left ventricular function. (DOSAGE AND ADMINI...
II. Dosing Limits A. Quantity Limit (max daily dose) [NDC Unit]:• Kadcyla 100 mg single-dose vial: 1 vial every 21 days • Kadcyla 160 mg single-dose vial: 3 vials every 21 days B. Max Units (per dose and over time) [HCPCS Unit]:• 480 billable units every 21 days III....
KADCYLA treatment should be permanently discontinued in the event of a life-threatening IRR [see Dosage and Administration (2.2)]. Patients should be observed closely for IRR reactions, especially during the first infusion. One case of a serious, allergic/anaphylactic-like reaction has been ...
确认有效率82.7%;NCCN指南推荐二线1类首选治疗复发性不可切除(局部或区域)或IV期HER2+疾病的其他名称 赫赛莱,Ado-trastuzumab emtansine 剂型 注射液 生产厂家 F. Hoffmann-La Roche Ltd 罗氏 规格 100 mg/瓶 160 mg/瓶 在线咨询 微信客服 400-001-9769 正品保障 全球速递 客服咨询 隐私保护 ...
Dosage and Administration Ado‐trastuzumab emtansine is available as Kadcyla in lyophilized powder in single-dose vials containing 100 mg or 160 mg per vial. The recommended dose of Kadcyla for breast cancer is 3.6 mg/kg given as an intravenous infusion every 3 weeks (21-day cycle) until dise...